来法莫林对422株金黄色葡萄球菌药敏试验:梯度扩散条与纸片扩散法对比肉汤微量稀释法
该研究以肉汤微量稀释法(BMD)为参考,评估梯度扩散条(GDS)和纸片扩散法(DD)对422株金黄色葡萄球菌(256株MSSA、166株MRSA)来法莫林药敏试验的准确性。GDS分类一致率100%、基本一致率92.2%,无重大误差和极重大误差;DD分类一致率99.5%,但极重大误差率16.7%(1/6)。GDS满足CLSI标准但系统性低估MIC,DD非敏感结果需BMD确认。
要点
- GDS与BMD分类一致率100%,无重大误差和极重大误差,但MIC系统性偏低0.49 log₂。
- GDS MIC=0.25 mg/L时建议用BMD确认。
- DD分类一致率99.5%,但极重大误差率16.7%超过CLSI阈值,非敏感结果需BMD验证。
核心结论
- 来法莫林GDS满足CLSI标准但系统性低估MIC,BMD确认建议用于GDS MIC=0.25 mg/L。
- 纸片扩散法一致性极好,但因非敏感菌株稀少导致极重大误差率超过CLSI阈值,任何非敏感结果应经BMD验证。
研究设计与样本
- 以BMD为参考方法,同时测试GDS和DD,按CLSI M100-S34折点判读:MIC≤0.25 mg/L或抑菌圈直径≥23 mm为敏感。
- 计算分类一致率、基本一致率、重大误差和极重大误差。
主要发现
- BMD显示98.6%(416/422)的菌株对来法莫林敏感,6株非敏感(4株MSSA、2株MRSA)。
- GDS与BMD相比分类一致率100%、基本一致率92.2%,无极重大误差和重大误差,MIC较BMD低0.49 log₂。
- 20 µg来法莫林纸片扩散法分类一致率99.5%(421/422),极重大误差率16.7%(1/6),重大误差率0.2%(1/416)。
关键数值与推荐
- CLSI M100-S34折点:MIC≤0.25 mg/L或抑菌圈直径≥23 mm判为敏感。
- GDS:分类一致率100%,基本一致率92.2%,极重大误差0%,重大误差0%。
- 纸片扩散法(20 µg):分类一致率99.5%,极重大误差率16.7%(1/6),重大误差率0.2%(1/416)。
临床怎么用
- GDS可用于常规药敏试验,但当MIC=0.25 mg/L时建议用BMD确认。
- 纸片扩散法非敏感结果应经BMD验证后方可报告。
局限性
- 非敏感菌株数量少(仅6株),导致纸片扩散法极重大误差率估计不稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Lefamulin is a novel pleuromutilin antibiotic with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). While broth microdilution (BMD) is the reference method for susceptibility testing, simpler alternatives such as MIC Test Strip (gradient diffusion strip [GDS]) and disk diffusion (DD) are urgently needed for routine laboratories. We evaluated the accuracy of GDS and DD compared to BMD for lefamulin against S. aureus. A total of 422 non-duplicate clinical isolates of S. aureus (256 methicillin-susceptible S. aureus [MSSA] and 166 MRSA) collected between December 2023 and December 2024 at the Affiliated Tai'an Central Hospital of Qingdao University were tested by BMD, GDS, and DD. Interpretation followed CLSI M100-S34 breakpoints (MIC ≤ 0.25 mg/L or zone diameter ≥ 23 mm = susceptible). BMD served as the reference to calculate categorical agreement (CA), essential agreement (EA), major errors (ME), and very major errors (VME). Lefamulin exhibited potent activity against S. aureus, with 98.6% (416/422) of isolates classified as susceptible by BMD; six isolates (four MSSA and two MRSA) were non-susceptible. Compared with BMD, GDS showed 100% CA and 92.2% EA and yielded no VME and ME, and MICs were 0.49 log₂ lower than BMD. Disk diffusion with the 20 µg lefamulin disk achieved 99.5% CA (421/422), with a VME rate of 16.7% (1/6) and an ME rate of 0.2% (1/416). Lefamulin GDS fulfilled CLSI criteria but systematically underestimated MICs; BMD confirmation is advised for GDS MIC = 0.25 mg/L. Disk diffusion showed excellent agreement, yet its VME rate surpassed the CLSI threshold owing to scarce non-susceptible isolates; any non-susceptible result by disk should be verified by BMD. IMPORTANCE: Lefamulin is a new antibiotic active against methicillin-resistant Staphylococcus aureus, but simple susceptibility tests are lacking. We compared two easy-to-perform methods with reference broth microdilution for 422 S. aureus clinical isolates. Both showed high accuracy after on-site confirmation of borderline results and can be immediately implemented in routine laboratories to guide appropriate lefamulin therapy and help contain resistance.
引用
- Tian Y, He X, Wu X, et al. Performance of gradient diffusion strip and disk diffusion versus broth microdilution for lefamulin susceptibility testing of 422 Staphylococcus aureus isolates. J Clin Microbiol. 2026. PMID: 41575216. doi:10.1128/jcm.01578-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。